de Graaff B - Search Results

1

Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loréal O. Brissot P, et al. Among authors: de graaff b. Nat Rev Dis Primers. 2018 Apr 5;4:18016. doi: 10.1038/nrdp.2018.16. Nat Rev Dis Primers. 2018. PMID: 29620054 Free PMC article. Review.

2

A Systematic Review and Narrative Synthesis of Health Economic Studies Conducted for Hereditary Haemochromatosis.

de Graaff B, Neil A, Sanderson K, Si L, Yee KC, Palmer AJ. de Graaff B, et al. Appl Health Econ Health Policy. 2015 Oct;13(5):469-83. doi: 10.1007/s40258-015-0189-y. Appl Health Econ Health Policy. 2015. PMID: 26255179 Review.

3

Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia.

de Graaff B, Neil A, Si L, Yee KC, Sanderson K, Gurrin L, Palmer AJ. de Graaff B, et al. Appl Health Econ Health Policy. 2017 Aug;15(4):521-534. doi: 10.1007/s40258-016-0297-3. Appl Health Econ Health Policy. 2017. PMID: 28035629

4

Quality of life utility values for hereditary haemochromatosis in Australia.

de Graaff B, Neil A, Sanderson K, Yee KC, Palmer AJ. de Graaff B, et al. Health Qual Life Outcomes. 2016 Feb 29;14:31. doi: 10.1186/s12955-016-0431-9. Health Qual Life Outcomes. 2016. PMID: 26922941 Free PMC article.

5

Costs associated with hereditary haemochromatosis in Australia: a cost-of-illness study.

de Graaff B, Neil A, Sanderson K, Yee KC, Palmer AJ. de Graaff B, et al. Aust Health Rev. 2017 Jul;41(3):254-267. doi: 10.1071/AH15188. Aust Health Rev. 2017. PMID: 27444148

6

Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model.

de Graaff B, Si L, Neil AL, Yee KC, Sanderson K, Gurrin LC, Palmer AJ. de Graaff B, et al. Pharmacoecon Open. 2017 Mar;1(1):37-51. doi: 10.1007/s41669-016-0005-0. Pharmacoecon Open. 2017. PMID: 29442300 Free PMC article.

7

A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions.

Si L, Winzenberg TM, de Graaff B, Palmer AJ. Si L, et al. Among authors: de graaff b. Osteoporos Int. 2014 Aug;25(8):1987-97. doi: 10.1007/s00198-014-2636-2. Epub 2014 Feb 22. Osteoporos Int. 2014. PMID: 24562840 Review.

8

Need, want and demand: What is really happening with low-acuity presentations?

Neil A, de Graaff B. Neil A, et al. Among authors: de graaff b. Emerg Med Australas. 2016 Jun;28(3):363-4. doi: 10.1111/1742-6723.12591. Epub 2016 May 18. Emerg Med Australas. 2016. PMID: 27189418 No abstract available.

9

Up, up and away: The growth of after-hours MBS claims.

de Graaff B, Nelson M, Neil A. de Graaff B, et al. Aust Fam Physician. 2017 Jun;46(6):407-411. Aust Fam Physician. 2017. PMID: 28609598 Free article.

10

Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia.

de Graaff B, Yee KC, Clarke P, Palmer A. de Graaff B, et al. Appl Health Econ Health Policy. 2018 Aug;16(4):495-502. doi: 10.1007/s40258-018-0392-8. Appl Health Econ Health Policy. 2018. PMID: 29675692

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters